Wyant T - Search Results

1

Role of receptor occupancy assays by flow cytometry in drug development.

Stewart JJ, Green CL, Jones N, Liang M, Xu Y, Wilkins DE, Moulard M, Czechowska K, Lanham D, McCloskey TW, Ferbas J, van der Strate BW, Högerkorp CM, Wyant T, Lackey A, Litwin V. Stewart JJ, et al. Among authors: wyant t. Cytometry B Clin Cytom. 2016 Mar;90(2):110-6. doi: 10.1002/cyto.b.21355. Epub 2016 Feb 16. Cytometry B Clin Cytom. 2016. PMID: 26704557 Free article. Review.

2

Recommendations for the development and validation of flow cytometry-based receptor occupancy assays.

Green CL, Stewart JJ, Högerkorp CM, Lackey A, Jones N, Liang M, Xu Y, Ferbas J, Moulard M, Czechowska K, Mc Closkey TW, van der Strate BW, Wilkins DE, Lanham D, Wyant T, Litwin V. Green CL, et al. Among authors: wyant t. Cytometry B Clin Cytom. 2016 Mar;90(2):141-9. doi: 10.1002/cyto.b.21339. Epub 2016 Feb 22. Cytometry B Clin Cytom. 2016. PMID: 26566147 Free article. Review.

3

Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab.

Wyant T, Estevam J, Yang L, Rosario M. Wyant T, et al. Cytometry B Clin Cytom. 2016 Mar;90(2):168-76. doi: 10.1002/cyto.b.21236. Epub 2015 Apr 27. Cytometry B Clin Cytom. 2016. PMID: 25908521 Free article. Clinical Trial.

4

Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist.

Wyant T, Lackey A, Green M. Wyant T, et al. J Transl Med. 2008 Dec 1;6:76. doi: 10.1186/1479-5876-6-76. J Transl Med. 2008. PMID: 19046455 Free PMC article. Clinical Trial.

5

In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.

Wyant T, Yang L, Fedyk E. Wyant T, et al. MAbs. 2013 Nov-Dec;5(6):842-50. doi: 10.4161/mabs.26392. MAbs. 2013. PMID: 24492340 Free PMC article.

6

Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease.

Wyant T, Yang L, Lirio RA, Rosario M. Wyant T, et al. J Clin Pharmacol. 2021 Sep;61(9):1174-1181. doi: 10.1002/jcph.1877. Epub 2021 Jul 14. J Clin Pharmacol. 2021. PMID: 33908636 Free PMC article.

7

Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition.

Estevam J, Danaee H, Liu R, Ecsedy J, Trepicchio WL, Wyant T. Estevam J, et al. Among authors: wyant t. J Immunol Methods. 2011 Jan 5;363(2):135-42. doi: 10.1016/j.jim.2010.09.021. Epub 2010 Sep 29. J Immunol Methods. 2011. PMID: 20887727

8

Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.

Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG. Parikh A, et al. Among authors: wyant t. Inflamm Bowel Dis. 2012 Aug;18(8):1470-9. doi: 10.1002/ibd.21896. Epub 2011 Dec 6. Inflamm Bowel Dis. 2012. PMID: 22147460 Clinical Trial.

9

Whole blood microvolume laser scanning cytometry for monitoring resting and activated platelets.

Wyant TL, Smith PC, Brown B, Kantor AB. Wyant TL, et al. Platelets. 2001 Aug;12(5):309-18. doi: 10.1080/09537100120068206. Platelets. 2001. PMID: 11487384 Free article.

10

Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.

Milch C, Wyant T, Xu J, Parikh A, Kent W, Fox I, Berger J. Milch C, et al. Among authors: wyant t. J Neuroimmunol. 2013 Nov 15;264(1-2):123-6. doi: 10.1016/j.jneuroim.2013.08.011. Epub 2013 Aug 31. J Neuroimmunol. 2013. PMID: 24067534

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters